research

Tectonic Therapeutic, Inc. (TECX) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Seeking Alpha

2 min read

0 likes

⚡ Quantum Brief

Tectonic Therapeutics, led by CEO Alise Reicin, presented at the TD Cowen 46th Annual Health Care Conference in March 2026, highlighting its focus on GPCR-targeting biologics for high-unmet-need diseases. The company’s pipeline includes two clinical-stage programs (covering three indications) and a growing preclinical portfolio, targeting multibillion-dollar markets with limited existing therapies. Its lead candidate, TX45, is a long-acting relaxin in Phase II trials for pulmonary hypertension and heart failure, addressing preserved ejection fraction—a critical unmet medical need. Tectonic’s leadership boasts deep industry experience, with over 20 first-in-class drug approvals collectively, emphasizing data-driven decision-making and pipeline flexibility. The presentation underscored the firm’s strategic emphasis on agonist/antagonist biologics, positioning it as a key player in GPCR-focused drug development.

AI Audio Summary

0:00 / 0:00

Click to play

Quantum News · Media Library

Understand this faster with AI

Ask ChatGPT

Research with Perplexity

Explain with Claude

Discuss on Grok

SA Transcripts158.86K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Tectonic Therapeutic, Inc. (TECX) TD Cowen 46th Annual Health Care Conference March 4, 2026 11:10 AM EST Company Participants Alise Reicin - President, CEO, Secretary & Director Conference Call Participants Tyler Van Buren - TD Cowen, Research Division Presentation Tyler Van BurenTD Cowen, Research Division Good morning, everyone.

Tyler Van Buren here, Senior Biotech Analyst at TD Cowen. Thank you very much for joining TD Cowen's 46th Annual Healthcare Conference for our next session. Looking forward to a hybrid presentation and fireside with Tectonic Therapeutics. And it's my pleasure to introduce Dr. Alise Reicin, President and CEO of Tectonic. Alise, it's a privilege to have you here. Thank you for joining me. I'll hand it over to you for the presentation. Alise ReicinPresident, CEO, Secretary & Director Thank you for inviting me. In the next 10 to 15 minutes, I'm trying to give you a very high-level overview of what we're doing at Tectonic. Here is our forward-looking statement. And just to get started. Tectonic is focused for any of you that don't know, on the discovery and development of both agonist and antagonist biologics targeting GPCRs. We have a super experienced executive team. Between us, we've led teams that have resulted in over 20 first approvals drugs and many follow-up indications. Our focus to date has been on high unmet need areas with limited to no therapeutic options with multibillion-dollar market potential. When we started the company, our goal was to have a robust product pipeline that enables optionality and good data-based decisions. And as of today, we have 2 programs in the clinic covering 3 indications as well as a strong emerging preclinical pipeline. First, we have TX45, our long-acting relaxin, which is in Phase II for pulmonary hypertension associated with preserved ejection fraction and heart failure. You'll hear me refer to that

Read Original

Source Information

Source: Seeking Alpha

Website: https://seekingalpha.com/feed.xml

Discussion

0 professional contributions

Be the first to add a constructive contribution.